NEUROONE MEDICAL TECHNOLOGIES Corp
Financial highlights
| Metric | FY September 30, 2025 | FY September 30, 2024 | FY September 30, 2023 | FY September 30, 2022 | FY September 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $9.1M | $3.5M | $2.0M | $171,169 | $178,146 |
| Gross profit | $5.1M | $1.1M | $456,517 | -$70,794 | -$97,749 |
| Operating income | -$4.2M | -$11.9M | -$12.0M | -$10.0M | -$10.2M |
| Operating expenses | $12.4M | $13.0M | $13.9M | $11.9M | $10.2M |
| Cost of revenue | $4.0M | $2.4M | $1.5M | $241,963 | $275,895 |
| Cash from operations | -$2.8M | -$11.0M | -$12.9M | -$7.5M | -$8.6M |
| Capital expenditure | $81,742 | $120,197 | $384,117 | $275,226 | $67,079 |
| Free cash flow | -$2.9M | -$11.1M | -$13.3M | -$7.8M | -$8.7M |
| Share repurchases | $124,617 | $81,403 | $119,419 | — | — |
| Total assets | $10.8M | $5.4M | $8.1M | $12.8M | $7.9M |
| Total liabilities | $3.7M | $4.5M | $1.8M | $3.2M | $1.4M |
Shares outstanding 8.6M · Free float 79.4%
Annual filing data through FY ended September 30, 2025; float as of July 4, 2026.